Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 18:17:13 23/05/2024 BST 5-day change 1st Jan Change
164.4 USD +0.64% Intraday chart for Moderna, Inc. +22.97% +64.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney... Our Logo
The market is good to go until Nvidia’s next quarterly results Our Logo
News Highlights : Top Company News of the Day - Thursday at 9 AM ET DJ
News Highlights : Top Company News of the Day - Thursday at 3 AM ET DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET DJ
Health Care Up as Vaccine Makers Gain - Health Care Roundup DJ
News Highlights : Top Company News of the Day - Wednesday at 5 PM ET DJ
US IS IN 'ACTIVE CONVERSATIONS' WITH MRNA VACCINE MAKERS PFIZER… RE
Moderna Insider Sold Shares Worth $1,909,863, According to a Recent SEC Filing MT
Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care Stocks Softer Friday Afternoon MT
Sector Update: Health Care MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program MT
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports RE
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program MT
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner RE
Merck to present new oncology data CF
Investors need more than PPI to make up their minds Our Logo
ANALYST RECOMMENDATIONS : Nike, Roblox, Starbucks, Walmart, Deckers Outdoor... Our Logo
Evercore ISI Initiates Moderna With In Line Rating, $120 Price Target MT
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3 USD
Average target price
138.5 USD
Spread / Average Target
-15.19%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Moderna Insider Sold Shares Worth $936,981, According to a Recent SEC Filing